Extended Data Fig. 2: Forest plot of subgroup analysis for overall survival according to baseline characteristics and selected prognostic factors. | Nature Medicine

Extended Data Fig. 2: Forest plot of subgroup analysis for overall survival according to baseline characteristics and selected prognostic factors.

From: Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

Extended Data Fig. 2

HR and associated 95% CI were estimated using Cox proportional-hazards models with Breslow’s method of tie handling. CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; IHC, immunohistochemistry; OS, overall survival; PD-L1, programmed death-ligand 1; ref, reference subgroup.

Back to article page